Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237176 | 0.91 | NPSR1 (0.83) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL16217105 | 0.87 | TSHR (1.00) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL11715064 | 0.83 | NPSR1 (0.81) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL20965403 | 0.80 | L3MBTL1 (0.78) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL12835479 | 0.79 | ALDH1A1 (1.00) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL17502633 | 0.78 | NPSR1 (0.76) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL14758418 | 0.77 | TSHR (0.82) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL18051872 | 0.77 | NPSR1 (0.74) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL1520673 | 0.75 | NPSR1 (1.00) | TSHRLMNANPSR1RAB9ASMN1; SMN2 | |
| SCHEMBL9857776 | 0.75 | NPSR1 (0.71) | TSHRLMNANPSR1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893096-B2 | For example, N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1 H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide; administering the compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2258365-A1 | Use of organic compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20060257852-A1 | Severe acute respiratory syndrome coronavirus | CHIRON CORPORATION (US) | 2006-11-16 | — | — | US | disclosed |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | CHIRON CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060257852-A1 | Severe acute respiratory syndrome coronavirus | SARS1, ACE2, ACE | TSHR 4432/4885LMNA 2336/4885NPSR1 2040/4885 |
| US-20050136065-A1 | Use of small molecule compounds for immunopotentiation | ICOS, CD14, LCP2 | TSHR 3732/4885LMNA 4862/4885NPSR1 3843/4885 |
| US-20110104186-A1 | Small molecule immunopotentiators and assays for their detection | ICOS, CD14, MAVS | TSHR 3916/4885LMNA 4870/4885NPSR1 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.